Novartis: Favourable court ruling on Entresto
(CercleFinance.com) - In a brief press release, Novartis is pleased to announce that the US Court of Appeals for the Federal Circuit (CAFC) has upheld the validity of its Entresto (sacubitril/valsartan) combination patent.
We will strive to appropriately enforce the combination patent throughout its pediatric exclusivity period expiring in July 2025, the Swiss pharmaceutical giant says.
Novartis adds that it will also continue to defend and protect all its important intellectual property and regulatory rights relating to Entresto, for which there is currently no generic version available in the US.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
We will strive to appropriately enforce the combination patent throughout its pediatric exclusivity period expiring in July 2025, the Swiss pharmaceutical giant says.
Novartis adds that it will also continue to defend and protect all its important intellectual property and regulatory rights relating to Entresto, for which there is currently no generic version available in the US.
Copyright (c) 2025 CercleFinance.com. All rights reserved.